key: cord-0885085-hqr2zskr authors: Wei, Zhi‐Yao; Qian, Hai‐Yan; Huang, Ji; Geng, Yong‐Jian title: Pathogenesis and Management of Myocardial Injury in Coronavirus Disease 2019 date: 2020-07-19 journal: Eur J Heart Fail DOI: 10.1002/ejhf.1967 sha: ecf3f5f8366c3fcb492440f0eb7bea2e2209af01 doc_id: 885085 cord_uid: hqr2zskr The outbreak of coronavirus disease 2019 (COVID‐19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection, has become a major health crisis and a worldwide pandemic. COVID‐19 is characterized by high infectivity, long incubation period, diverse clinical presentations, and strong transmission intensity. COVID‐19 can cause myocardial injury as well as other cardiovascular complications, particularly in senior patients with pre‐existing medical conditions. The current review summarizes the epidemiological characteristics, potential mechanisms, clinical manifestations, and recent progress in the management of COVID‐19 cardiovascular complications. In December 2019, a virus-associated disease, predominately characterized by pneumonia, emerged and quickly spread around the world. The disease outbreak has triggered a major health crisis in many countries throughout the world and is now named coronavirus disease 2019 (COVID-19) officially by World Health organization 1 . The pathogen causing COVID-19 has been attributed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus closely related to severe acute respiratory syndrome coronavirus (SARS-CoV) 2 . SARS-CoV-2 is the third member of coronaviruses family known to cause life-threatening disease, following SARS-CoV and middle east respiratory syndrome Accepted Article This article is protected by copyright. All rights reserved. The cardiovascular system is highly vulnerable to the tissue injury caused by . The pathogenesis of myocardial injury has been demonstrated by recent autopsy reports from different investigators 9 10 . The exact mechanism for the development of COVID-19 cardiovascular complications has not been fully understood. COVID-19 may damage the heart directly or indirectly or both (Figure 1 ). The occurrence of myocardial injury is generally diagnosed when the serum levels of troponin I/T (TnI/T) increase above the 99th percentile upper reference limit after excluding TnI/T elevation related to obstructive coronary artery disease, according to the fourth universal definition of myocardial infarction 9 . The incidence of myocardial injury in COVID-19 ranges from 7.2% to 40.9% in general cohorts 5, [10] [11] [12] [13] [14] [15] [16] [17] [18] . TnI/T elevation appears much more striking in severe patients and non-survivors [19] [20] [21] . Recent reports on the prevalence and description of myocardial injury are summarized in Table 2 . In a recent study enrolling 191 patients, the myocardial injury occurred in 46% of non-survivors, compared with only about 1% of discharged patients 11 . Myocardial injury appears to serve as an independent risk factor for the severity and mortality of COVID-19, with reported hazard ratio ranging from 4.3 to 8.9 12, 13, 22 , and odds ratio from 6.6 to 26.9 14, 23, 24 in different studies. Furthermore, some of the deceased patients show dynamic elevation of TnT levels during hospitalization, whereas discharged patients or survivors showed no change in TnT levels, suggesting that Accepted Article This article is protected by copyright. All rights reserved. 6 aggravated myocardial injury is associated with adverse COVID-19 prognosis 15, 19 . Electrocardiographic and echocardiographic findings for COVID-19 patients with myocardial injury are generally normal 13 . Specific electrocardiographic and imaging abnormality are usually diagnosed as acute myocarditis [25] [26] [27] [28] . Inciardi In addition to the direct myocardial injury caused by viral infection, other cardiovascular complications may occur in COVID-19, in particular acute vascular events, which may contribute to the development of myocardial injury and dysfunction. This article is protected by copyright. All rights reserved. In a study of 184 intensive unit care (ICU) patients with COVID-19, up to 31% of them presented with thromboembolic complications, including 27% with venous thromboembolism and 3.7% with arterial thrombotic events, even though all patients had received standard doses of thromboprophylaxis 29 . In a New York hospital, reportedly, several young and previously healthy COVID-19 patients were found to suffer from an abnormally high incidence of stroke 30 . In another study, patients diagnosed as disseminated intravascular coagulation (DIC) accounted for 71.4% of non-survivors but occurred only in 0.6% of survivors 31 . Activated partial thromboplastin time (APTT) and prothrombin time (PT) were decreased in 16% and 30% of COVID-19 patients 32 . Moreover, levels of D-dimer were significantly higher among those who died of COVID-19 versus those who survived and a subsequent study identified an abnormal D-dimer level (>1 μg/L) as a major risk factor for death 11 , also suggesting that coagulation abnormality contributes to mortality. The above findings reveal a high prevalence of thromboembolic events during the development of COVID-19, and support the necessity of closely monitoring the status of coagulation and thrombosis in hospitalized patients 33 . Acute heart failure represents another common cardiovascular complication of COVID-19, especially in patients undergoing clinical deterioration 11, 18, 34 . In the history of deceased patients, plasma NT-proBNP levels often showed dynamic Accepted Article This article is protected by copyright. All rights reserved. elevation during hospitalization, revealing the close relationship between cardiac dysfunction and disease severity 15 . The new-onset myocardial injury is partly responsible for acute cardiac failure, described by several case reports as discussed above 25, 26 . Clearly, with COVID-19 progression, there is a positive correlation between the levels of NT-proBNP and TnT (R 2 =0.376, P<0.001) 15 . Nearly 50% of COVID-19 patients developing heart failure had a history of cardiovascular diseases, suggesting that the decompensation of underlying cardiovascular conditions also strongly contributes to the acute cardiac dysfunction 18 . An increased risk of arrhythmia has been recently reported in patients with SARS-CoV-2 infection 13 . Electro physiologically, COVID-19 patients are prone to the development of tachycardia. A study of 112 COVID-19 patients reported that 29.5% of patients presented with tachycardia, and other evidence for myocardial injury 13 . The heart rate of COVID-19 patients appeared to be correlated with troponin levels, suggesting the link of tachycardia to myocardial injury in COVID-19. In addition to tachycardia, malignant arrhythmia and following cardiac arrest may occur in COVID-19 patients, specifically in those with myocardial injury 15 , which might lead to sudden cardiac death, reportedly responsible for 11.1% of deaths 35 . A French population-based study found that the out-hospital cardiac arrest incidence in the COVID-19 pandemic increased two times over that in the same weeks in the non-pandemic period 36 , and a third of the increase was caused by suspected or This article is protected by copyright. All rights reserved. confirmed COVID-19. Despite the high incidence of myocardial injury in COVID-19 patients, exact mechanisms underlying the pathogenesis of cardiac injury and dysfunction remain largely unclear. Molecular and cellular evidence and clinical data have disclosed multifactorial events and pathways which likely trigger or accelerate the micro-and macro-process of myocardial injury. The viral infection may provoke multiple pathogenic factors, which may directly or indirectly cause the impairment of cardiovascular cells by SARS-CoV-2 infection, as illustrated in Figure 1 . Similar to SARS-CoV, SARS-CoV-2 invades host cells through viral spike protein (S protein) binding to the ACE2 surface receptor 37 (Figure 2 ). Known as a negative regulator of the renin-angiotensin system (RAS), ACE2 plays a regulatory role in counter-balancing the bioactivity of ACE 38 . It can also initiate outside-in signaling as a membrane protein 39 . The specific cellular mechanism, by which SARS-CoV-2 damages cardiomyocytes, has not been clarified completely. SARS-CoV-2 shares a similar biological pathway with SARS-CoV. Both viruses rely on type II transmembrane serine proteases (TMPRSS2), another protein expressed on the cellular membrane, to cleave S protein and expose the receptor-binding domain to bind with ACE2. This S protein-ACE2 This article is protected by copyright. All rights reserved. binding leads to the endocytosis of virus particles 40 and may be followed by the downregulation of ACE2 expression in cardiomyocytes 41, 42 , and the over-activation of RAS. The downregulation of ACE2 associated with SARS-CoV infection is partly caused by the shedding of ACE2 ectodomain, mediated by TNF-α-converting enzyme (TACE) in coupling with the production of TNF-α, a well-known factor for pro-fibrosis and myocardial damage 43 . The Ras-ERK-AP-1 pathway may be triggered, as well as the activation of the C-C motif chemokine ligand 2 (CCL2, a pro-fibrosis factor) 44 . The above theories are supported by an autopsy report regarding SARS, showing the presence of SARS-CoV in the heart associated with marked down-regulation of ACE2 expression 42 . The interstitial fibrosis was observed in the heart tissues of SARS and COVID-19 patients with myocardial injury, implying the involvement of following pro-fibrotic effect 25, 42 . However, even though the identification of viral particles and viral genetic materials in the myocardium of COVID-19 cases has offered pathological evidence of viral myocardities 25, 45 , further investigation is needed to determine expression of ACE2 and its interactions with the virus and host cell components, which may help clarify the impacts of changed cellular ACE2 levels on the myocardial injury driven by SARS-CoV-2 infection. Pulmonary inflammation and dysfunction caused by SARS-CoV-2 infection limits the oxygen-blood exchange, and triggers hypoxemia, hypotension, and even septic Accepted Article This article is protected by copyright. All rights reserved. shock 46 . Consequently, insufficient oxygen supply may occur in vital organs, including the heart. Concomitantly, myocardial oxygen demand may be elevated by heightened temperature and high myocardial metabolic rate that augments the inflammatory burden and imbalance between oxygen supply and consumption 47 . Along with COVID-19 progression, this imbalance is increasingly aggravated and worsened by the development of metabolic acidosis, fluid or electrolyte disorder, and dysfunction of the neuro-humoral system 25 . Thus, myocardial injury in COVID-19 patients may be indirectly triggered or augmented, especially in those with pre-existing cardiovascular disorders and compromising myocardial reserve capacity, which may have already exhausted on the supply side 15 . In theory, SARS-CoV-2 may directly attack vascular endothelial cells, which also express high levels of ACE2 48 , leading to abnormal coagulation and microcirculatory disturbance. Intramural microvascular blood flow may be altered, causing regional ischemia, followed by focal myocardial injury and cardiac dysfunction 49 . Recent study 50 has shown that COVID-19 patients with DIC have a high incidence of myocardial injury. However, the detrimental effects of abnormal coagulation and microcirculatory disorders in myocardial injury need to be proved by further pathological evidence. Inflammation of small vessel walls and diffused microcirculatory thrombosis have been identified in liver and lung biopsy specimens from COVID-19 patients, However, so far, there has been a lack of convincing Accepted Article This article is protected by copyright. All rights reserved. evidence in the heart 51, 52 . Previous studies have confirmed that immune abnormalities contribute to many pathological changes in SARS-CoV and MERS-CoV infection 7, 53 . Specifically, the cytokine storm represents excessive and uncontrollable cytokine production in response to virus invasion and one of the main contributors to the pathogenic injury to the heart. The levels of serum pro-inflammatory cytokines [e.g., Interleukin-1β (IL-1β), IL-6, interferon-γ (IFN-γ)] are markedly increased in COVID-19 patients and associated with disease progression 5 . Interestingly, in the cytokine storm, Th2 anti-inflammatory cytokines, such as IL-4 and IL-10, are reportedly at high levels , and even related to the COVID-19 severity 18 . Asymptomatic patients exhibited lower levels of both pro-and anti-inflammatory cytokines than the symptomatic group, suggesting the pathogenic role of cytokines 54 . Among the inflammatory cytokines from anti-viral immune responses, IL-6 serves as a core component of the cytokine storm, expressing at significantly higher levels in COVID-19 patients with severe conditions and adverse prognosis, compared with those without 11, 18, 34 . IL-6 not only amplifies the cytokine storm by stimulating the production of other pro-inflammatory cytokines but also promoting vascular leakage and interstitial edema 55 . Moreover, IL-6 weakens papillary muscle contraction and causes myocardial dysfunction 56 . Increased levels of IL-6 occurred in many hospitalized COVID-19 patients, significantly associated with high hs-TnI levels 57 . This article is protected by copyright. All rights reserved. The COVID-19 associated myocardial injury occurs more frequently in the elderly with pre-existing cardiovascular comorbidities or risk factors, e.g., diabetes, hypertension, coronary heart disease, and chronic kidney disease 12, 15 , which are known independent risk factors for heart disease 22 . Given that pre-existing CVD and Accepted Article This article is protected by copyright. All rights reserved. in-hospital myocardial injury are both key determinants of COVID-19 fatality 12, 58 , it is not surprising that COVID-19 patients with the adverse conditions possess the highest mortality (69.4%), compared with patients without myocardial injury but with underlying CVD (13.3%) and patients with myocardial injury but without underlying CVD (37.5%), while the mortality in patients without myocardial injury or underlying CVD is the lowest (7.62%) 15 . However, these cardiac image changes may be, to a certain degree, attributable to pre-existing cardiac disorders 13 . Besides that, the abnormalities on echocardiography were mainly a small amount of pericardial effusion 13 droplets in endomyocardial specimens of COVID-19 patients 25 . Focal, mainly perivascular interstitial fibrosis, and large (>20 μm), vacuolated, CD68-positive macrophages with coronavirus particles inside were also found in the myocardium. However, so far, there has been no convincing evidence of cardiac intramural microcirculation dysfunction or thrombosis in COVID-19. Future researches are required to clarify the histopathologic characteristics of COVID-19-related myocardial injury. To date, treatment of COVID-19 has been mostly restricted to supportive care measures as few specific therapeutics have been available to treat this disease. Pre-existing poor-health conditions make patients more vulnerable to infection-induced cardiovascular complications, thus increasing related mortality risk 15 . Therefore, senior patients who have underlying cardiac conditions are highly vulnerable to COVID-19 cardiac injury, and they should be prioritized for clinical care. Regarding diagnostic criteria, the abnormal levels of myocardial biomarkers, especially TnI/T, constitute the main criteria to identify COVID-19 patients with myocardial injury. However, TnI/T changes may be affected by other determinants, such as the infection status, hypoxia, and renal insufficiency, which are commonly This article is protected by copyright. All rights reserved. observed with the development of COVID-19. The -rise-and-fall‖ pattern of TnI/T is also seen in patients with acute coronary syndrome (ACS). There may be a longer waiting period from the first symptom onset to receiving medical care during the COVID-19 pandemic than in the non-pandemic period. Hence, a comprehensive assessment of the heart function in COVID-19 patients should be performed using electrocardiography, imaging, and laboratory testing for proper clinical judgment in patients with abnormal TnI/T levels. However, even after comprehensive examinations, sometimes it remains hard to differentiate ACS from other TnI/T elevating conditions associated with COVID-19 59 . Therefore, it is essential to promptly perform coronary angiography and continue necessary primary percutaneous coronary intervention (PCI) for patients with suspected ACS. The primary PCI procedures used for ACS patients is favorably suitable to COVID-19 patients, even though elective coronary procedures in the catheterization laboratory are recommended to be temporarily suspended due to the COVID-19 pandemic 62,63 . Considering the high prevalence of thromboembolic complications in COVID-19 patients, it is essential to actively take prophylactic anticoagulation during hospitalization for the management of COVID-19, especially for severe COVID-19. A recent study involving 449 severe COVID19 patients found that treating with unfractionated heparin or low molecular weight heparin for at least 7 days could significantly reduce the mortality in patients meeting the criteria for sepsis-induced DIC, or in patients with markedly elevated D-dimer 64 progression, such as pro-arrhythmic medication effects, or electrolyte disturbances, identify and correct potential risk factors should be done in a high priority. This article is protected by copyright. All rights reserved. Since the outbreak of COVID-19, several anti-virus agents have been proposed and are currently under clinical investigation. Among them, the most hopeful one is remdesivir. This broad-spectrum investigational antiviral agent that was initially developed for treating Ebola virus infection but failed to show satisfactory efficacy in clinical trials 67 . In the first randomized controlled trial (RCT) regarding COVID-19, remdesivir showed little clinical benefit compared with placebo for serious COVID-19 patients 68 . However, this trial was terminated early, so it is underpowered to draw any definite conclusion. The second RCT enrolling 1063 participants showed that remdesivir is superior to control treatment in shortening the time to recovery (11 days vs. 15 days, P<0.001) and alleviating respiratory tract infection in adults hospitalized with COVID-19 69 . There is no significant difference in the mortality between the groups receiving remdesivir and placebo 69 . Nonetheless, remdesivir has offered new insight into the therapeutic approaches against the current global COVID-19 crisis. The pivotal role of immunologic overresponse in COVID-19 prompts anti-inflammatory therapy to be studied for treating COVID-19. Hydroxychloroquine and chloroquine are traditional anti-malarial drugs that can efficiently control the SARS-Cov-2 replication in vitro 70, 71 . The first study about hydroxychloroquine treatment regarding COVID-19 treatment is a small open-label, non-randomized study, This article is protected by copyright. All rights reserved. in which hydroxychloroquine administration was significantly associated with viral load reduction/disappearance 72 . However, a double-masked non-randomized trial has yielded conflicting results 73 , and increased prolongation of the QT interval was observed in patients who underwent hydroxychloroquine treatment 73, 74 . Hydroxychloroquine administration was not associated with a lowered risk of intubation or death in an observational study involving 1446 patients 75 This article is protected by copyright. All rights reserved. Targeted anti-inflammatory therapies, such as IL-6 blockade, have also been viewed as the potential therapeutic option, given the pivotal role of cytokine storm in the pathogenesis of COVID-19 and its cardiovascular complications. The anti-IL-6 receptor monoclonal antibody, tocilizumab, has been reported to quickly control fever and improve respiratory function of 21 severe COVID-19 patients 84 . However, an Italian RCT found that treatment with tocilizumab failed to reduce severe respiratory symptoms, intensive care visits, or death in patients with early-stage COVID-19 85 . Thus, there appears to be controversy regarding the efficacy of anti-IL-6 therapy in the COVID-19 cohorts. More data from patients in advanced-stage and severe conditions are hopefully coming up from ongoing RCT 86 . The structural evidence of SARS-Cov-2 entering the cell via ACE2 has led to the hypothesis that angiotensin-converting enzyme inhibitor (ACEI) and angiotensin receptor blockade (ARB) may potentially induce the overexpression of ACE2, and subsequently increase susceptibility to SARS-Cov-2 infection and aggravate disease severity 87 . However, ACEI/ARB appears to play a protective rather than a harmful role in COVID-19, given that the SARS-CoV-2 invasion may result in the activation of the RAS axis, which is partly responsible for severe organ injury of COVID-19 41 . Potential mechanisms in detail have been summarized elsewhere 88 . Growing evidence showed that COVID-19 patients under ACEI/ARB treatment had similar and even better clinical prognosis than those not 15, 16, 89, 90 . While several clinical trials are This article is protected by copyright. All rights reserved. looking for compelling evidence proving the usefulness and safety of ACEI/ARB in COVID-19 91, 92 , it is not recommendable to alter the routine anti-hypertensive therapy in COVID-19 patients. In the COVID-19 pandemic, patients with pre-existing medical conditions are vulnerable to myocardial injury as well as other cardiovascular complications. This article is protected by copyright. All rights reserved. All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication. SARS-CoV-2 invasion is mediated by the S protein binding to its ligand ACE2, which is primed by TMPRSS2 through cleaving S protein into S1 and S2 subunit to facilitate the exposure of RBD on S1 subunit The binding of RBD to ACE2 is followed by This article is protected by copyright. All rights reserved. World Health Organization. Coronavirus disease (COVID-19) outbreak Understanding of COVID-19 based on current evidence Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein COVID-19 map Acute myocarditis associated with novel Middle east respiratory syndrome coronavirus Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China Suspected myocardial injury in patients with COVID-19: Evidence from front-line clinical observation in Wuhan, China Analysis of myocardial injury in patients with COVID-19 and association between concomitant cardiovascular diseases and severity of COVID-19] (in Chinese) Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19) COVID-19 with Different Severity: A Multi-center Study of Clinical Features Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area Clinical characteristics of 113 deceased patients with coronavirus disease Accepted Article This article is protected by copyright. All rights reserved. 26 2019: retrospective study Clinical characteristics of 25 death cases with COVID-19: a retrospective review of medical records in a single medical center Analysis of 92 deceased patients with COVID-19 Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019 Acute Myocardial Injury at Hospital Admission is Associated with All-cause Mortality in COVID-19 Acute myocardial injury is common in patients with covid-19 and impairs their prognosis Myocardial localization of coronavirus in COVID-19 cardiogenic shock Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19) Accepted Article This article is protected by copyright. All rights reserved Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies China Medical Treatment Expert Group for C. Clinical Characteristics of Coronavirus Disease 2019 in China Myocardial Ischemia: Lack of Coronary Blood Flow or Myocardial Oxygen Supply/Demand Imbalance? Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis A clinicopathological study on cardiac lesions in 64 cases of disseminated intravascular coagulation Pathological findings of COVID-19 associated with acute respiratory distress syndrome Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology Clinical and immunological assessment of asymptomatic SARSCoV2 infections Immunotherapeutic implications of IL-6 blockade for cytokine storm Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock Heart injury signs are associated with higher and earlier mortality in coronavirus disease 2019 (COVID-19) Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis ST-Segment Elevation in Patients with Covid-19 -A Case Series Clinical and radiographic features of cardiac injury in patients with 2019 novel coronavirus pneumonia Accepted Article This article is protected by copyright. All rights reserved Considerations for cardiac catheterization laboratory procedures during the COVID-19 pandemic perspectives from the Society for Cardiovascular Angiography and Interventions Emerging Leader Mentorship (SCAI ELM) Members and Graduates Catheterization Laboratory Considerations During the Coronavirus (COVID-19) Pandemic: From the ACC's Interventional Council and SCAI Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy ISTH interim guidance on recognition and management of coagulopathy in COVID-19 Guidance on Minimizing Risk of Drug-Induced Ventricular Arrhythmia During Treatment of COVID-19: A Statement from the Canadian Heart Rhythm Society Controlled Trial of Ebola Virus Disease Therapeutics Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. the Remdesivir for the Treatment of Covid-19-Preliminary Report Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Team ftC-. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19 A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19 Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome SARS: systematic review of treatment effects Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin Accepted Article This article is protected by copyright. All rights reserved A cheap steroid is the first drug shown to reduce death in COVID-19 patients Effective treatment of severe COVID-19 patients with tocilizumab Roche rheumatoid arthritis drug fails to help COVID-19 patients in Italian study A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia (COVACTA).Identifier: NCT04320615 Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2 Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19 Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China research LHJC Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 ClinicalTrialsgov Losartan for Patients With COVID-19 Not Requiring Hospitalization. Identifier: NCT04311177 ClinicalTrialsgov Losartan for Patients With COVID-19 Requiring Hospitalization. Identifier: NCT04312009 Fischman DL COVID-19 complicated by Acute Pulmonary Embolism and Right-Sided Heart Failure Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan Acute pulmonary embolism and COVID-19 pneumonia: a random association? This article is protected by copyright. All rights reserved. Accepted Article This article is protected by copyright. All rights reserved. Accepted Article This article is protected by copyright. All rights reserved.receptor-mediated endocytosis Activation of the renin-angiotensin system, upregulation of the TNF-α pathway and the Ras pathway following ACE2 attachment can injure cells/tissues that highly express ACE2 *These mechanisms are speculated based on SARS-CoV studies and the similarity of two viruses Accepted Article This article is protected by copyright. All rights reserved. 15, 35 Accepted Article This article is protected by copyright. All rights reserved. Abbreviation: COVID-19, coronavirus disease 2019; NT-proBNP, N-terminal pro-B-type natriuretic peptide; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; TnI/T, troponin I/T * No incidence data available † Only patients suspected of having pulmonary embolism underwent computer tomography pulmonary angiography, so the real incidence may be lower ‡ Incidence in severe or deceased cohorts This article is protected by copyright. All rights reserved.